Silence Therapeutics plc
SLN
$5.35
-$0.11-2.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 57.75% | -99.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 57.75% | -99.44% | |||
| Cost of Revenue | 57.41% | -97.61% | |||
| Gross Profit | 57.95% | -99.62% | |||
| SG&A Expenses | -33.22% | 13.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.79% | 37.81% | |||
| Operating Income | 21.23% | -479.80% | |||
| Income Before Tax | 4.16% | -247.52% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.12% | -375.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.12% | -375.94% | |||
| EBIT | 21.23% | -479.80% | |||
| EBITDA | 21.38% | -469.59% | |||
| EPS Basic | 4.14% | -375.97% | |||
| Normalized Basic EPS | 8.82% | -247.56% | |||
| EPS Diluted | 4.14% | -375.97% | |||
| Normalized Diluted EPS | 8.82% | -247.56% | |||
| Average Basic Shares Outstanding | 0.01% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||